Inflammatory Bowel Disease Treatment Market Trends That Will Shape the Next Decade: Insights from Verantos Launches AI-Driven Inflammatory Bowel Disease Pragmatic Registry to Enhance Treatment Research

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Inflammatory Bowel Disease Treatment Market Size By 2025?
Recent years have witnessed a significant surge in the size of the inflammatory bowel disease treatment market. The market, which is predicted to amplify from $25.26 billion in 2024 to $27.19 billion in 2025, anticipates a compound annual growth rate (CAGR) of 7.6%. Factors such as the rising incidence of inflammatory bowel disease, a growing demand for biologics and immunomodulators, progress in treatment mediators, uptick in the elderly populace, and heightened disease awareness can be credited for the growth in the historical timeframe.

How Big Is the Inflammatory Bowel Disease Treatment Market Size Expected to Grow by 2029?
There is an anticipation of robust expansion in the inflammatory bowel disease treatment market over the next few years. It is projected to inflate to "$39.39 billion by 2029, boasting a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth in the upcoming years include; increased expenditure on research and development initiatives, surging demand for biosimilars, escalating prevalence of inflammatory bowel disease in developing markets, increasing need for personalized medicines and incorporation of precision medicine in IBD care. The period's anticipated trends include a rise in the number of new product launches and approvals, individualized dosage and treatment strategies in IBD control, employment of telemedicine for IBD patient remote surveillance, investigations into microbiome-centric therapies for IBD, and embracing value-based care methods in IBD management.

View the full report here:
https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Which Key Market Drivers Powering Inflammatory Bowel Disease Treatment Market Expansion and Growth?
The escalating prevalence of Crohn's disease and ulcerative colitis is notably propelling the growth of the inflammatory bowel disease treatment market. These two conditions are forms of inflammatory bowel diseases (IBD) which lead to inflammation and the manifestation of ulcers or sores in the digestive tracts. Anticipated growth in the occurrence of Crohn's disease and ulcerative colitis is projected to galvanize demand for inflammatory bowel disease treatments, which are widely employed to mitigate bowel inflammation and curtail medical complications. For instance, research conducted in March 2022 and published in the United States National Library of Medicine - a U.S.-based medical library - revealed that nearly 1.6 million Americans are presently living with inflammatory bowel disease (either Crohn's disease or ulcerative colitis), and approximately 70,000 fresh cases of IBD are reported annually in the US. Consequently, the upward trend in the prevalence of Crohn's disease and ulcerative colitis is envisioned to fuel the growth of the inflammatory bowel disease treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Are the Key Trends Driving Inflammatory Bowel Disease Treatment Market Growth?
Progress in technology is a crucial trend gaining momentum in the inflammatory bowel disease treatment market. Top firms in this market are capitalizing on AI-augmented registries to gain a competitive advantage. For example, in May 2024, Verantos, a Californian firm specializing in real-world evidence (RWE), launched the Inflammatory Bowel Disease Pragmatic Registry. This leverages advanced AI to generate high-quality RWE for ulcerative colitis and Crohn's disease. The goal of this registry is to stimulate the production of efficient therapies through the provision of an extensive dataset containing more than 3 billion data points linked to patient care. The system enables biopharma researchers to achieve an in-depth understanding of disease severity, therapeutic efficacy, and clinical results, using both structured and unstructured data derived from electronic health records.

What Are the Emerging Segments in the Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market covered in this report is segmented -

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn's Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp

Who Are the Global Leaders in the Inflammatory Bowel Disease Treatment Market?
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

Which are the Top Profitable Regional Markets for the Inflammatory Bowel Disease Treatment Industry?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6704

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.